日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

帕博利珠单抗作为不适合顺铂治疗的晚期尿路上皮癌的一线疗法(KEYNOTE-052):老年患者按年龄和体能状态划分的疗效

Grivas, Petros; Plimack, Elizabeth R; Balar, Arjun V; Castellano, Daniel; O'Donnell, Peter H; Bellmunt, Joaquim; Powles, Thomas; Hahn, Noah M; de Wit, Ronald; Bajorin, Dean F; Ellison, Misoo C; Frenkl, Tara L; Godwin, James L; Vuky, Jacqueline

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

在日本复发性晚期尿路上皮癌患者中,帕博利珠单抗与化疗的疗效比较:KEYNOTE-045 III期试验的亚组分析

Nishiyama, Hiroyuki; Yamamoto, Yoshiaki; Sassa, Naoto; Nishimura, Kazuo; Fujimoto, Kiyohide; Fukasawa, Satoshi; Yokoyama, Minato; Enokida, Hideki; Takahashi, Kenichi; Tanaka, Yoshinobu; Imai, Kentaro; Shimamoto, Takashi; Perini, Rodolfo; Frenkl, Tara; Bajorin, Dean; Bellmunt, Joaquim

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

一项随机III期KEYNOTE-045试验比较了帕博利珠单抗与紫杉醇、多西他赛或长春氟宁治疗复发性晚期尿路上皮癌的疗效:超过2年的随访结果

Fradet, Y; Bellmunt, J; Vaughn, D J; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D P; Choueiri, T K; Necchi, A; Gerritsen, W; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Nam, K; Frenkl, T L; Perini, R F; de Wit, R; Bajorin, D F

Bladder dysfunction in mice with experimental autoimmune encephalomyelitis

实验性自身免疫性脑脊髓炎小鼠的膀胱功能障碍

Altuntas, Cengiz Z; Daneshgari, Firouz; Liu, Guiming; Fabiyi, Adebola; Kavran, Michael; Johnson, Justin M; Gulen, M Fatih; Jaini, Ritika; Li, Xiaoxia; Frenkl, Tara L; Tuohy, Vincent K

Echocardiographic characteristics of male athletes of different age

不同年龄段男性运动员的心动超声特征

Pavlik, G; Olexó, Z; Osváth, P; Sidó, Z; Frenkl, R